Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.
Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.
Bolt Biotherapeutics reported Q1 2022 financial results, showing collaboration revenue of $0.8 million, driven by R&D partnerships. R&D expenses rose to $18.4 million, reflecting progress in clinical trials and IND-enabling activities. General and administrative expenses increased to $6.3 million. The company holds a robust cash balance of $246.8 million, expected to fund operations and key milestones into 2024. The lead program, BDC-1001, is on track for data readouts in H2 2022, with promising early signs of clinical disease control.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotech firm, will present an overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 12:45 p.m. PT. The presentation will highlight Bolt's innovative immuno-oncology therapeutics that utilize Boltbody™ to target tumors. Key products include BDC-1001, a HER2-targeting agent in a Phase 1/2 trial, and others targeting CEA and Dectin-2. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event.
Bolt Biotherapeutics (BOLT) reported its financial results for Q4 and the full year 2021, showcasing a cash balance of $271.6 million to fund operations through 2024. The company is progressing with BDC-1001, a treatment for HER2-expressing solid tumors, expected to reach Phase 2 dose identification later in 2022. The ongoing combination study with OPDIVO® is advancing well, showing promising stability and partial responses. R&D expenses rose to $75.7 million, reflecting increased clinical trial costs. Total revenue for 2021 was $1.3 million, marking growth from $0.2 million in 2020.
Bolt Biotherapeutics (Nasdaq: BOLT) will present three preclinical pipeline programs at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The company is focused on immuno-oncology therapeutics combining antibody precision with immune system power. Key presentations include BDC-2034, targeting CEA, expected to enter clinical development in late 2022; BDC-3042, a Dectin-2 targeting antibody anticipated for 2023; and a PD-L1-targeting ISAC. Each program shows promise in anti-tumor activity and future clinical development.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology firm, recently announced upcoming presentations at two key conferences in February 2022. The first is the Guggenheim 2022 Oncology Virtual Conference on February 9 at 10:00 a.m. PT, followed by the SVB Leerink Global Healthcare Conference on February 16 at 2:00 p.m. PT. Both events will feature fireside chats, available for live streaming on Bolt's website, with archived replays accessible for 90 days post-event.
Bolt focuses on innovative immuno-oncology agents, particularly its lead candidate, BDC-1001, targeting HER2-expressing tumors.
Bolt Biotherapeutics (Nasdaq: BOLT) announced the first patient has been dosed in a new combination arm of its Phase 1/2 clinical trial for BDC-1001, which is being evaluated alongside Bristol Myers Squibb’s OPDIVO® (nivolumab). This trial targets HER2-expressing solid tumors. Preliminary findings from the single-agent portion showed a safe profile, supporting the promising potential of BDC-1001. Bristol Myers Squibb is providing OPDIVO for the trial, while Bolt is responsible for execution costs.
Bolt Biotherapeutics (Nasdaq: BOLT) has appointed Nicole Onetto, M.D., to its Board of Directors as of December 14, 2021. Dr. Onetto brings 30 years of oncology experience from various pharmaceutical and biotech companies. Her expertise in clinical development will be crucial as Bolt advances its immuno-oncology programs. Dr. Ashish Khanna is stepping down from the board after serving since July 2018. The company focuses on developing innovative immuno-oncology agents, particularly using its Boltbody™ ISAC approach to treat HER2-expressing solid tumors.
Bolt Biotherapeutics (Nasdaq: BOLT) announced interim clinical data from its Phase 1/2 study of BDC-1001 at the ESMO I-O Congress 2021. The study involved 57 subjects with HER2-expressing solid tumors, showcasing a favorable safety profile and early signs of clinical activity. Notably, 13 of 40 evaluable subjects displayed clinical activity, with one maintaining a durable partial response for 52 weeks. The company plans to continue dose-escalation studies and initiate combination therapy with Opdivo® by year-end 2021, aiming for optimized drug exposure levels.
Bolt Biotherapeutics (BOLT) has announced the presentation of interim clinical data for BDC-1001 at the ESMO I-O Congress 2021, scheduled from December 8-11, 2021. This data includes insights from over 50 patients and highlights safety, tolerability, and early signs of clinical activity. The presentation will inform an ongoing Phase 1/2 study and support the initiation of a combination dose-escalation study with Opdivo by year-end. The poster will be accessible online starting December 6, 2021, at 12 p.m. CET, with a company conference call planned for the same date at 8:00 a.m. ET.
Bolt Biotherapeutics (Nasdaq: BOLT) announces the appointments of Brian O’Callaghan and Frank D. Lee to its Board of Directors, while Peter Moldt steps down. O’Callaghan brings 30 years of biopharmaceutical experience, crucial for advancing Bolt's immuno-oncology pipeline. Lee, with over 25 years in product development, enhances the company’s commercial strategy. CEO Randall Schatzman highlights the transformative year for Bolt, marked by its IPO and progress in clinical trials. The company focuses on developing immune-stimulating therapeutics targeting HER2-expressing tumors, with promising collaborations established.